Boston, Massachusetts-based biotech Ascidian Therapeutics on Wednesday announced a research deal and a licensing agreement worth up to $1.9B with Eli Lilly (LLY) to develop and market kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results